Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
Saba NF, Chaudhary R, Kirtane K, Marra A, Ekpenyong A, McCook-Veal A, Schmitt NC, Gross JH, Patel MR, Remick J, Bates JE, McDonald MW, Rudra SF, Stokes WA, Biernacki M, Song X, Slebos RJC, Liu Y, Steuer CE, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: ekpenyong a. Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202. Clin Cancer Res. 2024. PMID: 39167623 Clinical Trial.
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: ekpenyong a. Nat Med. 2024 Aug;30(8):2373. doi: 10.1038/s41591-024-03161-w. Nat Med. 2024. PMID: 38956200 No abstract available.
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Saba NF, Wong SJ, Nasti T, McCook-Veal AA, McDonald MW, Stokes WA, Anderson AM, Ekpenyong A, Rupji M, Abousaud M, Rudra S, Bates JE, Remick JS, Joshi NP, Woody NM, Awan M, Geiger JL, Shreenivas A, Samsa J, Ward MC, Schmitt NC, Patel MR, Higgins KA, Teng Y, Steuer CE, Shin DM, Liu Y, Ahmed R, Koyfman SA. Saba NF, et al. Among authors: ekpenyong a. JAMA Oncol. 2024 Jul 1;10(7):896-904. doi: 10.1001/jamaoncol.2024.1143. JAMA Oncol. 2024. PMID: 38780927 Clinical Trial.
Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage.
Pamulapati S, Abousaud M, Li Y, Ekpenyong A, Rudra S, Remick JS, Bates JE, Stokes WA, McDonald MW, Schmitt NC, El-Deiry MW, Patel MR, Steuer CE, Switchenko JM, Shin DM, Teng Y, Hammond A, Saba NF. Pamulapati S, et al. Among authors: ekpenyong a. Head Neck. 2024 Sep;46(9):2167-2177. doi: 10.1002/hed.27786. Epub 2024 May 2. Head Neck. 2024. PMID: 38695445
Harnessing the potential of African youth for transforming health research in Africa.
Adebisi YA, Jimoh ND, Bassey AE, Alaka HO, Marah M, Ngoma C, Ogunkola IO, Bouaddi O, Courage I, Abdelatif El-Abasiri RA, Boutahar R, Ogbodum MU, Ekpenyong AM, Uwizeyimana T, Oghenerukevwe OE, Olawade DB. Adebisi YA, et al. Among authors: ekpenyong am. Global Health. 2024 Apr 25;20(1):35. doi: 10.1186/s12992-024-01039-7. Global Health. 2024. PMID: 38664751 Free PMC article.
64 results